HER2 has emerged as a significant biomarker in UC, holding considerable therapeutic implications. Given the tumor-agnostic approval of T-DXd for patients with HER2 IHC 3+ expression, all patients with ...
In this review, we provide a concise overview of neoadjuvant systemic therapy in early-stage HER2-positive breast cancer, with a focus on various chemotherapy backbones and de-escalation strategies.
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein ...
In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.
Eli Lilly and Company (NYSE: LLY) today announced that new data from across its breast oncology portfolio and pipeline will ...
Some lung cancers manage to overcome a targeted drug therapy despite it showing initial success. Yale researchers have now ...
Nearly 40 years ago, researchers identified the epidermal growth factor (EGF) domain as a key component in mussel adhesive proteins. Since then, similar adhesive proteins have been discovered in a ...
Cancer-fighting antibody drugs are designed to penetrate tumor cells and release a lethal payload deep within, but too often ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback